Journal of Endocrinological Investigation

, Volume 12, Issue 3, pp 197–200 | Cite as

Cyproheptadine may act at the pituitary in Cushing’s disease: Evidence from CRF stimulation

  • J. R. Tucci
  • K. J. Nowakowski
  • I. M. D. Jackson
Case Report


Cyproheptadine has been reported to effect remissions in up to 50% of patients with Cushing’s disease presumably at a hypothalamic level. Endocrine studies including CRF testing were performed in a 37-year-old woman with Cushing’s disease. Cyproheptadine therapy resulted in a clinical and chemical remission. During therapy, basal plasma and urinary steroid levels were normal as were responses to dexamethasone, metyrapone, and insulin induced hypoglycemia. CRF administration in the untreated patient resulted in a markedly exaggerated increase in plasma ACTH and cortisol levels, while with cyproheptadine therapy responses were considerably blunted but still greater than normal. These observations are the first to provide evidence supporting a pituitary effect of cyproheptadine in Cushing’s disease in vivo and raise questions regarding the assumption of hypothalamic dysfunction in those patients with Cushing’s disease responding to cyproheptadine.


Cushing’s disease cyproheptadine CRF hypothalamus pituitary 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stone C.A., Wenger H.C., Ludden C.T., Stavorski J.M., Ross C.A. Antiserotonin-anthihistaminic properties of cyproheptadine. J. Pharmacol. Exp. Ther. 131: 73, 1961.Google Scholar
  2. 2.
    Gilbert J.C., Goldbert L.I. Characterization by cyproheptadine of the dopamine-induced contraction in canine isolated arteries. J. Pharmacol. Exp. Ther. 193: 435, 1975.PubMedGoogle Scholar
  3. 3.
    Krieger D.T. Cyproheptadine: drug therapy for Cushing’s disease. In: Muller E.E. (Eds.), Neuroactive drugs in endocrinology. Elsevier/North-Holland, Biomedical Press, 1980, p. 361.Google Scholar
  4. 4.
    Jones M.T., Birmingham M., Gillham B., Holmes M., Smith T. The effect of cyproheptadine on the release of corticotrophin-releasing factor. Clin. Endocrinol. (Oxf.) 10: 203, 1979.CrossRefGoogle Scholar
  5. 5.
    Krieger D.T. Physiopathology of Cushing’s disease. Endocr. Rev. 4: 22, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    George W.F., Jusain M., Lock J.P., Katz F.H. Failure of cyproheptadine to inhibit vasopressin-stimulated cortisol release in a. patient with Cushing’s disease. Horm. Res. 7: 308, 1982.CrossRefGoogle Scholar
  7. 7.
    Plonk J., Feldman J.M. Modification of adrenal function by the antiserotonin agent cyproheptadine. J. Clin. Endocrinol. Metab. 42: 291, 1976.PubMedCrossRefGoogle Scholar
  8. 8.
    Suda T., Demura H., Demura R., Jibiki K., Tozawa F., Shizume K. Anterior pituitary hormones in plasma and pituitaries from patients with Cushing’s disease. J. Clin. Endocrinol. Metab. 51: 1048, 1980.PubMedCrossRefGoogle Scholar
  9. 9.
    Suda T., Tozawa F., Mouri T., Sasaki A., Shibasaki T., Demura H., Shizume K. Effects of cyproheptadine, reserpine and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing’s disease. J. Clin. Endocrinol. Metab. 56: 1094, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Ishibashi M., Yamaji T. Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. J. Clin. Invest. 68: 1018, 1981.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Lamberts S.W.J., Verleun T., Bons E.G., Utterlinden P., Oosteram R. Effect of cyproheptadine, desmethylcyproheptadine, γ-amino-butyric acid and sodium valproate on adrenocorticotrophin secretion by cultured pituitary tumor cells from three patients with Nelson’s syndrome. J. Endocrinol. 96: 401, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Silber R.H., Porter C.C. The determination of 17, 21-dihydroxy-20-ketosteroids in urine and plasma. J. Biol. Chem. 210: 923, 1954.PubMedGoogle Scholar
  13. 13.
    Peterson R.E., Carrer A., Guerra S.L. Evaluation of the Silber-Porter procedure for determination of plasma hydrocortisone. Anal. Chem. 29: 144, 1957.CrossRefGoogle Scholar
  14. 14.
    Henke W.J., Doe R.P., Jacobson M.E. A test of pituitary reserve utilizing intravenous SU-4885, with a new method for extraction of 11 -desoxycorticosteroids. J. Clin. Endocrinol. Metab. 20: 1527, 1960.PubMedCrossRefGoogle Scholar
  15. 15.
    Chrousos G.P., Schuermeyer T.H., Doppman J., Oldfield M.D., Schulte H.M., Gold P.W., Loriaux D.L. Clinical applications of corticotropin-releasing factor. Ann. Intern. Med. 102: 344, 1985.PubMedCrossRefGoogle Scholar
  16. 16.
    Gold P.W., Loriaux D.L., Roy A., Kling M.A., Calabrese J.R., Kellner C.H., Nieman L.K., Post R.M., Pickar D., Gallucci W., Avgerinos P., Paul S., Oldfield E.H., Cutler G.B., Jr., Chrousos G.P. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. N. Engl. J. Med. 314: 1329, 1986.PubMedCrossRefGoogle Scholar
  17. 17.
    Orth D.N., DeBold C.R., DeCherney G.S., Jackson R.V., Alexander A.N., Rivier J., Rivier C., Spiess J., Vale W. Pituitary microadenomas causing Cushing’s disease respond to corticotropin-releasing factor. J. Clin. Endocrinol. Metab. 55: 1017, 1982.PubMedCrossRefGoogle Scholar
  18. 18.
    Burch W.M. Cushing’s disease. A review. Arch. Intern. Med. 145: 1106, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Daughaday W.H. Cushing’s disease and basophilic microadenomas. N. Engl. J. Med. 310: 919, 1984.PubMedCrossRefGoogle Scholar
  20. 20.
    Carpenter P.C. Cushing’s syndrome: Update of diagnosis and management. Mayo Clin. Proc. 61: 49, 1986.PubMedCrossRefGoogle Scholar
  21. 21.
    Lamberts S.W.J., DeLange S.A., Stefanko S.Z. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing’s disease: Differences in the regulation of hormone secretion. J. Clin. Endocrinol. Metab. 54: 286, 1982.PubMedCrossRefGoogle Scholar
  22. 22.
    Van Cauter E., Refetoff S. Evidence for two subtypes of Cushing’s disease based on the analysis of episodes of Cortisol secretion. N. Engl. J. Med. 312: 1343, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Pieters G.F.F.M., Smals A.G.H., Goverde H.J.M., Pesman G.J., Meyer E., Kloppenborg P.W.C. Adrenocorticotropin and cortisol responsiveness to thyrotropin-releasing hormone and luteinizing hormone-releasing hormone discloses two subsets of patients with Cushing’s disease. J. Clin. Endocrinol. Metab. 55: 1188, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1989

Authors and Affiliations

  • J. R. Tucci
    • 1
  • K. J. Nowakowski
    • 1
  • I. M. D. Jackson
    • 1
  1. 1.Roger Williams General Hospital, Division of Endocrinology and MetabolismBrown University Program in MedicineProvidenceUSA

Personalised recommendations